Buscar resultados de ensayos clínicos
Lymphoma, Mantle-Cell - 25 Studies Found
Estado | Estudiar |
Terminated |
Nombre del estudio: Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) Condición: Lymphoma, Mantle-Cell Fecha: 2015-05-23 Intervenciones: Drug: Copanlisib (BAY80-6946) Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). A |
Active, not recruiting |
Nombre del estudio: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma Condición:
|
Active, not recruiting |
Nombre del estudio: A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Condición:
|
Active, not recruiting |
Nombre del estudio: EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma Condición:
|
Active, not recruiting |
Nombre del estudio: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2011-03-24 Intervenciones:
|
Completed |
Nombre del estudio: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2007-12-19 Intervenciones: Drug: modified Hyper-CVAD rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorub |
Completed |
Nombre del estudio: Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2007-12-19 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) Condición: Mantle Cell Lymphoma Fecha: 2011-08-16 Intervenciones:
|
Terminated |
Nombre del estudio: A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma Condición: Mantle Cell Lymphoma Fecha: 2009-02-12 Intervenciones: Drug: P276-00 P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 m |
Active, not recruiting |
Nombre del estudio: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma Condición: CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma Fecha: 2013-08-23 Intervenciones: Drug: rituximab |